Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)

View ORCID ProfileAndré Peralta-Santos, Eduardo Freire Rodrigues, Joana Moreno, Vasco Ricoca, Pedro Casaca, Eugenia Fernandes, View ORCID ProfileJoão Paulo Gomes, Rita Ferreira, Joana Isidro, Miguel Pinto, Vítor Borges, Luís Vieira, Sílvia Duarte, Carlos Sousa, José Pedro Almeida, Luís Menezes, Bibiana I. Ferreira, Ana Matias, Ana Pelerito, Samanta Freire, Teresa Grilo, Cláudia Medeiros Borges, Vera Moutinho, Andreia Leite, Irina Kislaya, Ana Paula Rodrigues, Pedro Pinto Leite, Baltazar Nunes
doi: https://doi.org/10.1101/2022.01.20.22269406
André Peralta-Santos
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for André Peralta-Santos
  • For correspondence: aperaltasantos@dgs.min-saude.pt
Eduardo Freire Rodrigues
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joana Moreno
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasco Ricoca
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Casaca
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugenia Fernandes
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
João Paulo Gomes
4Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for João Paulo Gomes
Rita Ferreira
4Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joana Isidro
4Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel Pinto
4Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vítor Borges
4Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luís Vieira
5Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sílvia Duarte
5Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Sousa
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Pedro Almeida
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luís Menezes
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bibiana I. Ferreira
7Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Matias
8Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, Faro, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Pelerito
9Portuguese Red Cross Laboratory, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samanta Freire
9Portuguese Red Cross Laboratory, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Grilo
9Portuguese Red Cross Laboratory, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cláudia Medeiros Borges
10Administração Central do Sistema de Saúde, IP (ACSS, Health System Central Administration)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Moutinho
11Serviços Partilhados do Ministério da Saúde, EPE (SPMS, Shared Services for Ministry of Health)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreia Leite
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Kislaya
12Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Paula Rodrigues
12Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Pinto Leite
1Direção de Serviços de Informação e Análise, Direcao-Geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baltazar Nunes
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
12Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Early reports showed that Omicron (BA.1) SARS-CoV-2 could be less severe. However, the magnitude of risk reduction of hospitalization and mortality of Omicron (BA.1) infections compared with Delta (B.1.617.2) is not yet clear. This study compares the risk of severe disease among patients infected with the Omicron (BA.1) variant with patients infected with Delta (B.1.617.2) variant in Portugal.

Methods We conducted a cohort study in individuals diagnosed with SARS-CoV-2 infection between 1st and 29th December 2021. Cases were individuals with a positive PCR test notified to the national surveillance system. SARS-CoV-2 variants were classified first by whole genomic sequencing (WGS) and, if this information was unavailable, by detecting the S gene target failure. We considered a hospitalization for all the patients admitted within the 14 days after the SARS-CoV-2 infection; after that period, they were censored.

The comparison of the risk of hospitalization between Omicron and Delta VOC was estimated using a Cox proportional hazards model. The mean length of stay was compared using linear regression, and the risk of death between Omicron and Delta patients was estimated with a penalized logistic regression. All models were adjusted for sex, age, previous infection, and vaccination status.

Results We included 15 978 participants aged 16 or more years old, 9 397 infected by Delta (B.1.617.2) and 6 581 infected with Omicron (BA.1). Within the Delta (B.1.617.2) group, 148 (1.6%) were hospitalized, and 16 (0.2%) were with the Omicron (BA.1). A total of 26 deaths were reported, all in participants with Delta (B.1.617.2) infection. Adjusted HR for hospitalization for the Omicron (BA.1) variant compared with Delta (B.1.617.2) was 0.25 (95%CI 0.15 to 0.43). The length of stay in hospital for Omicron (BA.1) patients was significantly shorter than for Delta (confounding-adjusted difference -4.0 days (95%CI -7.2 to -0.8). The odds of death were 0.14 (95% CI 0.0011 to 1.12), representing a reduction in the risk of death of 86% when infected with Omicron (BA.1) compared with Delta (B.1.617.2).

Conclusion Omicron was associated with a 75% risk reduction of hospitalization compared with Delta (B.1.617.2) and reduced length of hospital stay.

Competing Interest Statement

APS - Has stocks of pharmaceutical companies and is in an advisory board of a COVID-19 drug

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Portuguese National Institute of Health gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest: None

  • Funding statement: None

  • Data Availability Statement: data can be provided by the data owners upon reasonable request

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 23, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
André Peralta-Santos, Eduardo Freire Rodrigues, Joana Moreno, Vasco Ricoca, Pedro Casaca, Eugenia Fernandes, João Paulo Gomes, Rita Ferreira, Joana Isidro, Miguel Pinto, Vítor Borges, Luís Vieira, Sílvia Duarte, Carlos Sousa, José Pedro Almeida, Luís Menezes, Bibiana I. Ferreira, Ana Matias, Ana Pelerito, Samanta Freire, Teresa Grilo, Cláudia Medeiros Borges, Vera Moutinho, Andreia Leite, Irina Kislaya, Ana Paula Rodrigues, Pedro Pinto Leite, Baltazar Nunes
medRxiv 2022.01.20.22269406; doi: https://doi.org/10.1101/2022.01.20.22269406
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
André Peralta-Santos, Eduardo Freire Rodrigues, Joana Moreno, Vasco Ricoca, Pedro Casaca, Eugenia Fernandes, João Paulo Gomes, Rita Ferreira, Joana Isidro, Miguel Pinto, Vítor Borges, Luís Vieira, Sílvia Duarte, Carlos Sousa, José Pedro Almeida, Luís Menezes, Bibiana I. Ferreira, Ana Matias, Ana Pelerito, Samanta Freire, Teresa Grilo, Cláudia Medeiros Borges, Vera Moutinho, Andreia Leite, Irina Kislaya, Ana Paula Rodrigues, Pedro Pinto Leite, Baltazar Nunes
medRxiv 2022.01.20.22269406; doi: https://doi.org/10.1101/2022.01.20.22269406

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1435)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10334)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2654)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (571)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1335)
  • Ophthalmology (403)
  • Orthopedics (153)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2421)
  • Public and Global Health (5032)
  • Radiology and Imaging (902)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)